A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients With Previously Untreated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Key
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response Rate
Until disease progression
No
United States: Food and Drug Administration
PPHM 1001
NCT01160601
June 2010
July 2013
Name | Location |
---|---|
Community Hospital | Munster, Indiana 46321 |
Presbyterian Hospital | Charlotte, North Carolina 28233-3549 |
Dartmouth Hitchcock Medical Center | Lebanon, New Hampshire 03756 |
The Center for Cancer and Hematologic Disease | Cherry Hill, New Jersey 08003 |
Gabrail Cancer Center | Canton, Ohio 44718 |
San Juan Oncology Associates | Farmington, New Mexico 87401 |
Southeast Nebraska Cancer Center | Lincoln, Nebraska 68510 |
Baptist Cancer Institute | Jacksonville, Florida 32207 |
Cedar Valley Medical Specialists, PC | Waterloo, Iowa 50702 |
The Christ Hospital Cancer Center Research | Cincinnati, Ohio 45219 |
Signal Point Clinical Research Center, LLC | Middletown, Ohio 45042 |
Gettysburg Cancer Center | Gettysburg, Pennsylvania 17325 |
Ironwood Cancer and Research Center | Chandler, Arizona 85224 |
American Institute of Research | Whittier, California 90603 |
Baptist Clinical Research | Jonesboro, Arkansas 72401 |
Hematology-Oncology of Knoxville/Mercy Medical Center | Knoxville, Tennessee 37909 |
Delta Hematology Oncology Associates, PC | Portsmouth, Virginia 23704 |